glycopyrrolate has been researched along with fluticasone propionate, salmeterol xinafoate drug combination in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 6 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tashkin, DP | 1 |
| Alagappan, VK; Banerji, D; Bateman, ED; Chen, H; D'Andrea, P; Pallante, J; Vogelmeier, CF | 1 |
| Banerji, D; Humphries, M; Patalano, F; Thach, C; Wang, C; Wang, L; Zhang, N; Zhong, N; Zhou, X | 1 |
| Ayers, RT; Banerji, D; Chapman, KR; Fogel, R; Patalano, F; Roche, N; Thach, C; Vestbo, J; Vogelmeier, CF; Wedzicha, JA | 1 |
| Donohue, JF | 1 |
| Bader, G; Banerji, D; Fogel, R; Humphries, MJ; Mezzi, K; Patalano, F; Vogelmeier, C; Zhong, N | 1 |
| Banerji, D; Fogel, R; Fucile, S; Kostikas, K; Mezzi, K; Shen, S; Tsiligianni, I | 1 |
| Bjermer, L; Costa-Scharplatz, M; Gutzwiller, FS; Keininger, DL; Lisspers, K; Mahon, R; Olsson, P; Roche, N; van Boven, JFM | 1 |
| Burke, C; Chow, WL; Guruprasad, B; Tee, A | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Goyal, P; Guerin, T; Hurst, JR; Kostikas, K; Larbig, M; Patalano, F; Pfister, P; Wedzicha, JA | 1 |
| Anzueto, AR; Banerji, D; Fogel, R; Kostikas, K; Larbig, M; Mezzi, K; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Ashmawi, S; Backer, A; Diaz, DV; Frith, PA; Gurgun, A; Hamann, AM; Hristoskova, S; Kostikas, K; Krishnamurthy, S; Olsson, P; Pilipovic, V | 1 |
| Kasak, V; Klimes, J; Skoupa, J; Valena, T | 1 |
| Fogel, R; Fucile, S; Goyal, P; Jenkins, C; Kostikas, K; Mezzi, K; Shen, S; Singh, D; Tsiligianni, I; Wedzicha, JA | 1 |
| Banerji, D; Frent, SM; Gupta, P; Kostikas, K; Mackay, AJ; Olsson, P; Patalano, F; Pfister, P; Roche, N; Wedzicha, JA | 1 |
| Danyliv, A; Gutzwiller, FS; Lakhotia, B; Mahon, R; Nikolaev, I; Thokala, P | 1 |
| Chapman, KR; D'Andrea, P; Hosoe, M; Kerstjens, HAM; Lavecchia, C; Maspero, J; Pethe, A; Shu, X; Tanase, AM; van Zyl-Smit, RN | 1 |
| Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT | 1 |
| Andaloro, S; Bonavita, O; Crimi, C; Crimi, N; Morini, P; Pelaia, C; Pelaia, G; Ricciardi, L; Rizzi, A; Scichilone, N; Valenti, G | 1 |
| Bates, JHT; Cortellini, M; De Backer, W; Galkin, D; Georges, G; Guasconi, A; Lavon, BR; Panni, I; Skloot, GS | 1 |
11 trial(s) available for glycopyrrolate and fluticasone propionate, salmeterol xinafoate drug combination
| Article | Year |
|---|---|
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sympathomimetics; Treatment Outcome | 2013 |
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Sex Factors; Tiotropium Bromide; Vital Capacity | 2017 |
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.
Topics: Aged; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Economic; Population Surveillance; Pulmonary Disease, Chronic Obstructive; Quinolones; Sweden | 2017 |
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Bronchodilator Agents; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Treatment Outcome | 2018 |
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Drug Monitoring; Drug Substitution; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Treatment Outcome | 2018 |
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sex Characteristics; Treatment Outcome | 2019 |
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires | 2020 |
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Mometasone Furoate; Muscarinic Antagonists; Nebulizers and Vaporizers; Quinolones; Treatment Outcome; Young Adult | 2020 |
9 other study(ies) available for glycopyrrolate and fluticasone propionate, salmeterol xinafoate drug combination
| Article | Year |
|---|---|
Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Sympathomimetics | 2013 |
Another Choice for Prevention of COPD Exacerbations.
Topics: Adrenergic beta-2 Receptor Agonists; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.
Topics: Aged; Bronchodilator Agents; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Hospitals; Humans; Indans; Male; Middle Aged; Probability; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinolones; Singapore | 2018 |
Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Czech Republic; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinolones | 2018 |
Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Markov Chains; Pulmonary Disease, Chronic Obstructive; Quinolones; Sweden; Treatment Outcome | 2020 |
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines | 2021 |
Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Asthma; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Muscarinic Antagonists; Quinolones | 2022 |
The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Bronchodilator Agents; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2023 |